Shares of Panacea Biotec Limited surged over 4% in early trade after the company announced a major milestone in the development of its tetravalent dengue vaccine candidate, DengiAll®. The rally reflects renewed investor confidence following the completion of participant enrolment for the Phase III clinical trial in India.
In a regulatory filing issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Panacea Biotec confirmed that enrolment for the Phase III study has been successfully completed with 10,335 participants. This update follows the company’s earlier communication dated August 14, 2024, when it had informed exchanges about the initiation of the late-stage clinical trial.
With enrolment now concluded, the company will continue to closely monitor each study participant for a period of two years after the administration of the investigational medicinal product, which includes either the vaccine or a placebo. This extended observation phase is aimed at thoroughly evaluating the efficacy and immunogenicity of the dengue vaccine candidate, a critical step before regulatory approvals can be sought.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
